SEC Form SC 13G/A filed by Karuna Therapeutics Inc. (Amendment)
$KRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2023 | $291.00 | Buy | Citigroup |
| 12/12/2023 | $227.00 | Buy | Deutsche Bank |
| 8/22/2023 | $225.00 | Overweight | Wells Fargo |
| 7/20/2023 | $280.00 | Overweight | Morgan Stanley |
| 3/8/2023 | $214.00 | Neutral | Cantor Fitzgerald |
| 1/27/2023 | $209.00 | Neutral | UBS |
| 1/5/2023 | $285.00 | Overweight | Piper Sandler |
| 11/1/2022 | $288.00 | Buy | Loop Capital |
15-12G - Karuna Therapeutics, Inc. (0001771917) (Filer)
S-8 POS - Karuna Therapeutics, Inc. (0001771917) (Filer)
S-8 POS - Karuna Therapeutics, Inc. (0001771917) (Filer)
Citigroup initiated coverage of Karuna Therapeutics with a rating of Buy and set a new price target of $291.00
Deutsche Bank initiated coverage of Karuna Therapeutics with a rating of Buy and set a new price target of $227.00
Wells Fargo initiated coverage of Karuna Therapeutics with a rating of Overweight and set a new price target of $225.00
Jonathan Rosin appointed to Chief Human Resources Officer Jason Brown promoted to Chief Financial Officer Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Jonathan Rosin to Chief Human Resources Officer (CHRO) and the promotion of Jason Brown to Chief Financial Officer (CFO). Mr. Brown succeeds Troy Ignelzi, who will remain at Karuna for a transition period through the end of the third quarter of 2023. "These executive appointments are a key part of our transition to a fully integrated organization
Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Will Kane as chief commercial officer (CCO), effective February 6, 2023. "The addition of Will to our executive team represents an important step as we execute on our plan to transition Karuna to a fully integrated R&D and commercial organization," said Bill Meury, president and chief executive officer, Karuna Therapeutics. "Will is an exceptional leader and has extensive commercial operations experience, which will be invaluable as we focus our attention o
Mr. Meury is a distinguished pharmaceutical leader with more than 25 years of operational and commercial experience delivering transformative medicines to patients Succeeds current president, chief executive officer, and chairman, Steve Paul, M.D., who will transition to president of research and development and chief scientific officer Christopher Coughlin to assume role of chairman of the board Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Bill Meury as president and chief executive officer (CEO) a
Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for Seaport, and the $14 billion acquisition of Karuna by Bristol Myers Squibb Robust balance sheet with PureTech level cash, cash equivalents and short-term investments of $326.0 million3 and consolidated cash, cash equivalents and short-term Investments of $327.1 million4 as of December 31, 2023 As of March 31, 2024, PureTech level cash, cash equivalents and short-term investments were $573.3 million,5 enabling the support of Internal Programs and Founded Entities, future innovations, shareholder re
New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults under review with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024 Results from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia published in The Lancet Announced appointments of Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as General Counsel Previously announced proposed acquisition of Karuna by Bristol Myers Squibb expected to close in the first half of 2024 $1.3 billion in cash, cash equivalents, and available-for-sale investment securities Karuna Therapeutics, Inc. (NASDAQ:KRTX), a biopharmaceutical company driven to discover,
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer's Disease Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024 Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics c
4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer's Disease Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024 Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics c
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer's Disease Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024 Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET Bristol Myers Squibb (NYSE:BMY) and Karuna Therapeutics, Inc. (NASDAQ:KRTX) ("Karuna") today announced that they
Karuna Therapeutics, Inc. (NASDAQ:KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, November 2, 2023 at 8:00 a.m. ET to review third quarter 2023 financial results and provide a general business update. A live webcast of the presentation will be available on the Investor Relations page of Karuna's website at investors.karunatx.com. A replay of the webcast will also be archived for up to 30 days on Karuna's website following the completion of the event. About Karuna Therapeutics Karuna Therapeu
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Karuna Therapeutics (NASDAQ:KRTX) with a Neutral and maintains $330 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Karuna Therapeutics (NASDAQ:KRTX) with a Neutral and maintains $330 price target.
Hedge funds are steering clear of the booming artificial intelligence (AI) market and other technology stocks that have led the market rally over the past year. Instead, they are placing their bets on the healthcare sector, revealing a calculated move towards stability and value. According to the Goldman Sachs Hedge Funds Monitor, hedge funds are heavily favoring the healthcare sector, allocating to it over 600 basis points beyond the benchmark’s weight. In the S&P 500, the healthcare sector boasts a 12.8% weight, while tech nearly 30%. For the median hedge fund portfolio as of the end of Q4 2023, healthcare a weight of nearly 20%, while tech was underweighted by six percentage points
SC 13G - Karuna Therapeutics, Inc. (0001771917) (Subject)
SC 13G/A - Karuna Therapeutics, Inc. (0001771917) (Subject)
SC 13G/A - Karuna Therapeutics, Inc. (0001771917) (Subject)